Leap Therapeutics logo
Leap Therapeutics
LPTX | NASDAQ
Chart Builder DCF Calculator
$0.77
-$0.02 (-3.10%)
At close: Apr 01, 2026, 09:30 AM ET

Leap Therapeutics Company Profile

Company profile explained

Company Profile

Leap Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing treatments for various cancers. At the forefront of its pipeline is DKN-01, a monoclonal antibody designed to block Dickkopf-related protein 1 (DKK1). This investigational therapy is currently undergoing several clinical trials, targeting a range of malignancies such as esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics has also forged an option and licensing partnership with BeiGene, Ltd., granting them rights to develop and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Established in 2011, the company initially operated as HealthCare Pharmaceuticals, Inc., before rebranding to Leap Therapeutics, Inc. in November 2015. Its corporate headquarters are situated in Cambridge, Massachusetts.

Key Executives

Name Position
Douglas E. Onsi Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director

Latest SEC Filings

Date Type Title
Sep 25, 2026 3 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 22, 2026 8-K Current Report
Sep 02, 2026 8-K Current Report
Aug 27, 2026 4 Filing
Aug 26, 2026 144 Filing
Aug 24, 2026 4 Filing
Aug 24, 2026 3 Filing
Aug 19, 2026 4 Filing
View All SEC Filings ➞
Leap Therapeutics
Leap Therapeutics logo
Country United States
IPO Date Jan 25, 2017
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Douglas E. Onsi

Contact Details

47 Thorndike Street Cambridge, Massachusetts 02141 United States

Stock Details

Ticker Symbol LPTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001509745
CUSIP Number 52187K200
ISIN Number US52187K2006
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.